Chromosome 9p deletions are an independent predictor of tumor progression following nephrectomy in patients with localized clear cell renal cell carcinoma

Urologic Oncology: Seminars and Original Investigations

Volumn 32, Issue 5, 2014, Pages 601-606

  De Oliveira, Daniel ^a   Dall'Oglio, Marcos F ^a   Reis, Sabrina T ^a   Zerati, Marcelo ^a   Souza, Isida C ^a   Leite, Katia R ^a   Srougi, Miguel ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Carcinoma; Chromosome deletion; Chromosomes; Fluorescence; Humans pair 9; In situ hybridization; Prognosis; Renal cell

Indexed keywords

ADULT; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER LOCALIZATION; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RISK; CANCER SIZE; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CHROMOSOME 9P; CHROMOSOME DELETION; CHROMOSOME LOSS; CLINICAL ARTICLE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; HUMAN; KIDNEY CARCINOMA; MALE; NEPHRECTOMY; PREDICTION; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; AGED; CARCINOMA, RENAL CELL; CHROMOSOME 9; DISEASE COURSE; GENETICS; KIDNEY NEOPLASMS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 9; DISEASE PROGRESSION; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEPHRECTOMY; PROGNOSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84902498391     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2013.12.008     Document Type: Article

References (24)

1. Zisman A., Pantuck A.J., Wieder J., et al. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol 2002, 20:4559-4566.
2. Frank I., Blute M.L., Cheville J.C., et al. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol 2002, 168:2395-2400.
3. Dall'Oglio M.F., Ribeiro-Filho L.A., Antunes A.A., et al. Microvascular tumor invasion, tumor size and Fuhrman grade: a pathological triad for prognostic evaluation of renal cell carcinoma. J Urol 2007, 178:425-428.
4. Jones J., Out H., Spentzos D., et al. Gene signatures of progression and metastasis in renal cell cancer. Clin Cancer Res 2005, 11:5730-5739.
5. Soung-Sullivan P., Rao J., Cheng L., et al. Classical pathology versus molecular pathology in renal cell carcinoma. Curr Urol Rep 2007, 8:5-11.
6. Kim H.L., Seligson D., Liu X., et al. Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma. J Urol 2005, 173:1496-1501.
7. Klatte T., Rao P.N., de Martino M., et al. Cytogenetic profile predicts prognosis of patients with clear cell renal cell carcinoma. J Clin Oncol 2009, 27:746-753.
8. Schullerus D., Herbers J., Chudek J., et al. Loss of heterozygosity at chromosomes 8p, 9p, and 14q is associated with stage and grade of non-papillary renal cell carcinomas. J Pathol 1997, 183:151-155.
9. Presti J.C., Wilhelm M., Reuter V., et al. Allelic loss on chromosomes 8 and 9 correlates with clinical outcome in locally advanced clear cell carcinoma of the kidney. J Urol 2002, 167:1464-1468.
10. Brunelli M., Eccher A., Gobbo S., et al. Loss of chromosome 9p is an independent prognostic factor in patients with clear cell renal cell carcinoma. Mod Pathol 2008, 21:1-6.
11. La Rochelle J., Klatte T., Dastane A., et al. Chromosome 9p deletions identify an aggressive phenotype of clear cell renal cell carcinoma. Cancer 2010, 116:4696-4703.
12. Camp R.L., Charette L.A., Rimm D.L. Validation of tissue microarray technology in breast carcinoma. Lab Invest 2000, 80:1943-1949.
13. Varella-Garcia M. Stratification of non-small cell lung cancer patients for therapy with epidermal growth factor receptor inhibitors: the EGFR fluorescence in situ hybridization assay. Diagn Pathol 2006, 1:19-28.
14. Reid-Nicholson M.D., Motiwala N., Drury S.C., et al. Chromosomal abnormalities in renal cell carcinoma variants detected by Urovysion fluorescence in situ hybridization on paraffin-embedded tissue. Ann Diagn Pathol 2011, 15:37-45.
15. Bissig H., Richter J., Desper R., et al. Evaluation of the clonal relationship between primary and metastatic renal cell carcinoma by comparative genomic hybridization. Am J Pathol 1999, 155:267-274.
16. Kim S.P., Weight C.J., Leibovich B.C., et al. Outcomes and clinicopathologic variables associated with late recurrence after nephrectomy for localized renal cell carcinoma. Urology 2011, 78:1101-1106.
17. Chang L.L., Yeh W.T., Yang S.Y., et al. Genetic alterations of p16INK4a and p14ARF genes in human bladder cancer. J Urol 2003, 170:595-600.
18. Sherr C.J. The INK4a/ARF network in tumor suppression. Nat Rev Mol Cell Biol 2001, 2:731-737.
19. Cordon-Cardo C., Zhang Z.F., Dalbagni G., et al. Cooperative effects of p53 and pRB alterations in primary superficial bladder tumors. Cancer Res 1997, 57:1217-1221.
20. Ozenne P., Eymin B., Brambilla E., et al. The ARF tumor suppressor: structure, functions and status in cancer. Int J Cancer 2010, 127:2239-2247.
21. Gerlinger M., Rowan A.J., Horswell S., et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012, 366:883-892.
22. Parker A.S., Leibovich B.C., Lohse C.M., et al. Development and evaluation of BioScore: a biomarker panel to enhance prognostic algorithms for clear cell renal cell carcinoma. Cancer 2009, 115:2092-2103.
23. Kinkle D.A., Crispen P.L., Chen D.T., et al. Enhancing renal masses with zero net growth during active surveillance. J Urol 2007, 177:849-853.
24. Klatte T., Patard J.J., de Martino M., et al. Tumor size does not predict risk of metastasis disease or prognosis of small renal cell carcinomas. J Urol 2008, 179:1719-1726.